Sarcomatoid carcinoma arising in the pulmonary artery

Abstract

Background: Sarcomatoid carcinoma is a rare and aggressive malignancy with a poor prognosis, capable of arising in diverse tissues. Pulmonary artery sarcomatoid carcinoma is particularly uncommon and highly invasive.

Case Presentation: We present the case of a 40-year-old male who experienced dry cough and dyspnea, and was subsequently diagnosed with a mass obstructing the bilateral main pulmonary artery, predominantly involving the left main branch shortly after contracting COVID-19. Histopathological analysis of a lung biopsy and positron emission tomography (PET) scan confirmed the diagnosis of sarcomatoid carcinoma involving the bilateral main pulmonary artery. Following six cycles of combined chemotherapy and immunotherapy, the patient's condition remained relatively stable.

Conclusion: This case report aims to discuss the clinical presentation, diagnostic approach, and therapeutic management of this rare condition, thereby contributing to the broader understanding of sarcomatoid carcinoma.

Keywords

pulmonary sarcomatoid carcinoma / pulmonary artery / lung biopsy / COVID‐19

References

[1] Takeshima Y , Amatya VJ , Kushitani K , Kaneko M , Inai K . Value of immunohistochemistry in the differential diagnosis of pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma. Histopathology. 2009; 54 (6): 667- 676.

[2] Steuer CE , Behera M , Liu Y , et al. Pulmonary sarcomatoid carcinoma:an analysis of the National Cancer Data base. Clin Lung Cancer. 2017; 18 (3): 286- 292.

[3] Travis WD , Brambilla E , Nicholson AG , et al. The 2015 World Health Organization classification of lung tumors. J Thorac Oncol. 2015; 10 (9): 1243- 1260.

[4] Pelosi G , Sonzogni A , De Pas T , et al. Review article:pulmonary sarcomatoid carcinomas:a practical overview. Int J Surg Pathol. 2010; 18 (2): 103- 120.

[5] Li X , Wu D , Liu H , Chen J . Pulmonary sarcomatoid carcinoma: progress, treatment and expectations. Ther Adv Med Oncol. 2020; 12: 1758835920950207.

[6] Boland JM , Mansfield AS , Roden AC . Pulmonary sarcomatoid carcinoma-a new hope. Ann Oncol. 2017; 28 (7): 1417- 1418.

[7] Terra SBSP , Aubry MC , Yi ES , Boland JM . Immunohistochemical study of 36 cases of pulmonary sarcomatoid carcinoma-sensitivity of TTF-1 is superior to napsin. Hum Pathol. 2014; 45 (2): 294- 302.

[8] Shen XY , Lin ZF , Lin Q , et al. Pulmonary sarcomatoid carcinoma:a case report. Contemp Oncol (Poznan, Poland). 2013; 17 (2): 210- 213.

[9] Ouziane I , Boutayeb S , Mrabti H , Lalya I , Rimani M , Errihani H . Sarcomatoid carcinoma of the lung:a model of resistance of chemotherapy. N Am J Med Sci. 2014; 6 (7): 342.

[10] Aketa A , Yamada G , Aketa K , et al. Two younger male patients with rapidly progressing pulmonary pleomorphic carcinoma. Nihon Kokyuki Gakkai zasshi. 2004; 42 (2): 164- 169.

[11] Hou J , Xing L , Yuan Y . A clinical analysis of 114 cases of sarcomatoid carcinoma of the lung. Clin Exp Med. 2018; 18 (4): 555- 562.

[12] Tang W , Wen C , Pei Y , et al. Preoperative CT findings and prognosis of pulmonary sarcomatoid carcinoma:comparison with conventional NSCLC of similar tumor size. BMC Med Imaging. 2023; 23: 105.

[13] Vieira T , Girard N , Ung M , et al. Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma. J Thorac Oncol. 2013; 8 (12): 1574- 1577.

[14] Roesel C , Kambartel K , Kopeika U , Berzins A , Voshaar T , Krbek T . Lazarus-type tumour response to therapy with nivolumab for sarcomatoid carcinomas of the lung. Curr Oncol. 2019; 26 (2): e270.

[15] Li Y , Zhang L , Jiang J , et al. Clinical characteristics and prognostic analysis of 38 patients with pulmonary sarcomatoid carcinoma. Chin J Lung cancer. 2015; 18 (9): 537- 542.

[16] Maneenil K , Xue Z , Liu M , et al. Sarcomatoid carcinoma of the lung:the Mayo Clinic experience in 127 patients. Clin Lung Cancer. 2018; 19 (3): e323- e333.

[17] Sukrithan V , Sandler J , Gucalp R , Gralla R , Halmos B . Immune checkpoint blockade is associated with durable responses in pulmonary sarcomatoid carcinoma. Clin Lung Cancer. 2019; 20 (3): e242- e246.

[18] Reck M , Rodríguez-Abreu D , Robinson AG , et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016; 375 (19): 1823- 1833.

[19] Ota T , Niho S , Kirita K , Ishii G , Tsuboi M , Goto K . Impressive response to nivolumab of non-small-cell lung cancer containing sarcomatoid components. Respirol Case Rep. 2019; 7 (8): e00477.

[20] Mok TSK , Wu YL , Kudaba I , et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042):a randomised, open-label, controlled, phase 3 trial. Lancet. 2019; 393 (10183): 1819- 1830.

[21] De Castro G , Kudaba I , Wu YL , et al. Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non-small-cell lung cancer and programmed death ligand-1 tumor proportion score ≥ 1% in the KEYNOTE-042 study. J Clin Oncol. 2023; 41 (11): 1986- 1991.

[22] Martin LW , Correa AM , Ordonez NG , et al. Sarcomatoid carcinoma of the lung:a predictor of poor prognosis. Ann Thorac Surg. 2007; 84 (3): 973- 980.

[23] Ahn HK , Jung M , Ha SY , et al. Clinical significance of ki-67 and p53 expression in curatively resected non-small cell lung cancer. Tumor Biol. 2014; 35 (6): 5735- 5740.

[24] Lei B , Liu S , Qi W , et al. PBK/TOPK expression in non-small- cell lung cancer:its correlation and prognostic significance with Ki67 and p53 expression. Histopathology. 2013; 63 (5): 696- 703.

[25] Ciancio N , Galasso MG , Campisi R , Bivona L , Migliore M , Di Maria GU . Prognostic value of p53 and Ki67 expression in fiberoptic bronchial biopsies of patients with non small cell lung cancer. Multidiscip Respir Med. 2012; 7 (1): 29.

[26] Steels E , Paesmans M , Berghmans T , et al. Role of p53 as a prognostic factor for survival in lung cancer:a systematic review of the literature with a meta-analysis. Eur Respir J. 2001; 18 (4): 705- 719.

RIGHTS & PERMISSIONS

The Author(s). Malignancy Spectrum published by John Wiley & Sons Australia, Ltd on behalf of Higher Education Press.